{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:50:42Z","timestamp":1793922642357,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0877-4","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T09:03:50Z","timestamp":1533027830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4463-9757","authenticated-orcid":false,"given":"Wladimir","family":"Mauhin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Amelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foudil","family":"Lamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Dzangu\u00e9-Tchoupou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louiza","family":"Arouche-Delaperche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Dussol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Leguy-Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"D\u2019Halluin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Zenone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Matignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Maillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim-Heang","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolaine","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Labombarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Masseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Ziza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"877_CR2","volume-title":"GeneReviews(\u00ae) [Internet]","author":"A Mehta","year":"1993","unstructured":"Mehta A, Hughes DA. Fabry Disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(\u00ae) [Internet]. Seattle: University of Washington, Seattle; 1993. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1292\/\n                    \n                  . [cited 7 Jan 2016]."},{"key":"877_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44\u201354.","journal-title":"Clin Genet"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"e0161330","DOI":"10.1371\/journal.pone.0161330","volume":"11","author":"X Pan","year":"2016","unstructured":"Pan X, Ouyang Y, Wang Z, Ren H, Shen P, Wang W, et al. Genotype: a crucial but not unique factor affecting the clinical phenotypes in Fabry disease. PLoS One. 2016;11:e0161330.","journal-title":"PLoS One"},{"key":"877_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21:345\u201354.","journal-title":"Nephrol Dial Transplant"},{"key":"877_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18:1547\u201357.","journal-title":"J Am Soc Nephrol"},{"key":"877_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","volume":"3","author":"M Beck","year":"2015","unstructured":"Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry outcome survey analysis. Mol Genet Metab Rep. 2015;3:21\u20137.","journal-title":"Mol Genet Metab Rep"},{"key":"877_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, St\u00f6rk S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274:331\u201341.","journal-title":"J Intern Med"},{"key":"877_CR9","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66:1589\u201395.","journal-title":"Kidney Int"},{"key":"877_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"877_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"877_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0888-7543(91)90493-X","volume":"10","author":"AM Wang","year":"1991","unstructured":"Wang AM, Desnick RJ. Structural organization and complete sequence of the human alpha-N-acetylgalactosaminidase gene: homology with the alpha-galactosidase a gene provides evidence for evolution from a common ancestral gene. Genomics. 1991;10:133\u201342.","journal-title":"Genomics"},{"key":"877_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand S-M, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27:256\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"877_CR14","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","volume":"141","author":"M Lenders","year":"2018","unstructured":"Lenders M, Schmitz B, Brand SM, Foell D, Brand E. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. J Allergy Clin Immunol. 2018;141:2289\u201392. e7","journal-title":"J Allergy Clin Immunol"},{"key":"877_CR15","doi-asserted-by":"publisher","first-page":"e36373","DOI":"10.1371\/journal.pone.0036373","volume":"7","author":"M Namdar","year":"2012","unstructured":"Namdar M, Gebhard C, Studiger R, Shi Y, Mocharla P, Schmied C, et al. Globotriaosylsphingosine accumulation and not alpha-galactosidase-a deficiency causes endothelial dysfunction in Fabry disease. PLoS One. 2012;7:e36373.","journal-title":"PLoS One"},{"key":"877_CR16","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","volume":"26","author":"MD Sanchez-Ni\u00f1o","year":"2011","unstructured":"Sanchez-Ni\u00f1o MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26:1797\u2013802.","journal-title":"Nephrol Dial Transplant"},{"key":"877_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120:57\u201361.","journal-title":"Mol Genet Metab"},{"key":"877_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","volume":"117","author":"PS Kishnani","year":"2016","unstructured":"Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016;117:66\u201383.","journal-title":"Mol Genet Metab"},{"key":"877_CR19","doi-asserted-by":"crossref","unstructured":"Trampert DC, Hubers LM, van de Graaf SFJ, Beuers U. On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2017. Available from: \n                    http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0925443917302739\n                    \n                  . [cited 19 Sept 2017].","DOI":"10.1016\/j.bbadis.2017.07.038"},{"key":"877_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clim.2017.01.014","volume":"178","author":"Y Sato","year":"2017","unstructured":"Sato Y, Ida H, Ohashi T. Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice. Clin Immunol. 2017;178:56\u201363.","journal-title":"Clin Immunol"},{"key":"877_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, Oder D, Nowak A, Canaan-K\u00fchl S, Arash-Kaps L, Drechsler C, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017;282:241\u201353.","journal-title":"J Intern Med"},{"key":"877_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31\u201340.","journal-title":"Am J Hum Genet"},{"key":"877_CR23","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28:1631\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"877_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, et al. Anti-\u03b1-galactosidase a antibody response to agalsidase beta treatment: data from the Fabry registry. Mol Genet Metab. 2012;105:443\u20139.","journal-title":"Mol Genet Metab"},{"key":"877_CR25","doi-asserted-by":"publisher","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One. 2012;7:e47805.","journal-title":"PLoS One"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0877-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0877-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0877-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T19:13:56Z","timestamp":1564514036000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0877-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0877-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"20 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Legal authorizations were obtained from the Comit\u00e9 consultatif sur le traitement de l\u2019information en mati\u00e8re de recherche dans le domaine de la sant\u00e9 (n\u00b014.324bis) and the Comit\u00e9 de Protection des personnes Paris VI, according to the relevant French legislation.All patients signed written consent after specific oral and written information, for this research and its publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed written consent after specific oral and written information, for this research and its publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Inserm U974 research team received financial support from Shire, AFM-T\u00e9l\u00e9thon, SNFMI (Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne) and VML (Vaincre les Maladies Lysosomales) for this study.Wladimir Mauhin: Travel fees and accommodations: Shire, Orphan Europe, Amicus, Sanofi-Genzyme, honorarium: Shire.Olivier Lidove: Travel fees, accommodations and honorarium: Shire, Sanofi-Genzyme; honorarium: Amicus.Foudil Lamari: Travel fees and accommodations: Shire, Sanofi-Genzyme; Actelion Pharmaceuticals; honorarium Actelion Pharmaceuticals.Catherine Caillaud: Travel fees and accommodations: Sanofi-Genzyme; honorarium: Shire.Claire Douillard: Travel fees and accommodations: Shire, Sanofi-Genzyme.Bertrand Dussol: Honorarium: Amicus (member of the scientific board), Novartis (lectures), Travel fees: Genzyme-Sanofi, honorarium: Novartis.Vanessa Leguy-Seguin: Travel fees and accommodations: Shire, Sanofi-Genzyme.Esther Noel: Travel fees Shire, Sanofi-Genzyme; honorarium: Amicus.Thierry Zenone: Travel fees and accommodations: Sanofi-Genzyme; travel fees and honorarium: Shire.Fran\u00e7ois Maillot: Travel fees Shire, Sanofi-Genzyme; honorarium: Sanofi-Genzyme.G\u00e9rard Besson: honorarium: Shire.Fabien Labombarda: Travel fees and accommodations: Shire, Genzyme-Sanofi.Agathe Masseau: Travel fees and accommodations: Shire, Sanofi-Genzyme.Christian Lavigne: Travel fees and accommodations: Shire, Sanofi-Genzyme.Didier Lacombe: honorarium Genzyme Sanofi, Shire, Biomarin.Eric Hachulla: Honorarium: Sanofi-Genzyme, Shire; research grants: Sanofi-Genzyme; travel fees and accommodation: Sanofi-Genzyme, Shire.Olivier Benveniste: Travel fees Shire, LFB, CSL Behring; honorarium: Novartis, Neovacs, LFB.Damien Amelin, Louiza Arouche-Delaperche, Gaelle Dzangue-Tchoupou, Kim Heang Ly, Marjolaine Willems, Roseline Froissart, Marie B\u00e9n\u00e9dicte Matignon, Jean-Marc Ziza, Federico Mingozzi and Pauline d\u2019Halluin declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"127"}}